102 related articles for article (PubMed ID: 20570598)
1. Addition of a cysteine to glucagon-like peptide-1 (GLP-1) conjugates GLP-1 to albumin in serum and prolongs GLP-1 action in vivo.
Wu YL; Huang J; Xu J; Liu J; Feng Z; Wang Y; Lai Y; Wu ZR
Regul Pept; 2010 Sep; 164(2-3):83-9. PubMed ID: 20570598
[TBL] [Abstract][Full Text] [Related]
2. Modified human glucagon-like peptide-1 (GLP-1) produced in E. coli has a long-acting therapeutic effect in type 2 diabetic mice.
Xu F; Wang KY; Wang N; Li G; Liu D
PLoS One; 2017; 12(7):e0181939. PubMed ID: 28750064
[TBL] [Abstract][Full Text] [Related]
3. A mutated glucagon-like peptide-1 with improved glucose-lowering activity in diabetic mice.
Gao M; Tong Y; Gao X; Yao W
J Pharm Pharmacol; 2013 Apr; 65(4):539-46. PubMed ID: 23488782
[TBL] [Abstract][Full Text] [Related]
4. Mutated recombinant human glucagon-like peptide-1 protects SH-SY5Y cells from apoptosis induced by amyloid-beta peptide (1-42).
Qin Z; Sun Z; Huang J; Hu Y; Wu Z; Mei B
Neurosci Lett; 2008 Oct; 444(3):217-21. PubMed ID: 18760331
[TBL] [Abstract][Full Text] [Related]
5. Novel AGLP-1 albumin fusion protein as a long-lasting agent for type 2 diabetes.
Kim YM; Lee SM; Chung HS
BMB Rep; 2013 Dec; 46(12):606-10. PubMed ID: 24195794
[TBL] [Abstract][Full Text] [Related]
6. Development, characterization, and evaluation of a fusion protein of a novel glucagon-like peptide-1 (GLP-1) analog and human serum albumin in Pichia pastoris.
Gao Z; Bai G; Chen J; Zhang Q; Pan P; Bai F; Geng P
Biosci Biotechnol Biochem; 2009 Mar; 73(3):688-94. PubMed ID: 19270384
[TBL] [Abstract][Full Text] [Related]
7. Metabolic stability, receptor binding, cAMP generation, insulin secretion and antihyperglycaemic activity of novel N-terminal Glu9-substituted analogues of glucagon-like peptide-1.
Green BD; Gault VA; Irwin N; Mooney MH; Bailey CJ; Harriott P; Greer B; Flatt PR; O'Harte FP
Biol Chem; 2003 Dec; 384(12):1543-51. PubMed ID: 14719796
[TBL] [Abstract][Full Text] [Related]
8. Effects of long-term dipeptidyl peptidase-IV inhibition on body composition and glucose tolerance in high fat diet-fed mice.
Liu X; Harada N; Yamane S; Kitajima L; Uchida S; Hamasaki A; Mukai E; Toyoda K; Yamada C; Yamada Y; Seino Y; Inagaki N
Life Sci; 2009 Jun; 84(25-26):876-81. PubMed ID: 19358859
[TBL] [Abstract][Full Text] [Related]
9. A comparison of the cellular and biological properties of DPP-IV-resistant N-glucitol analogues of glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide.
Green BD; Gault VA; O'Harte FP; Flatt PR
Diabetes Obes Metab; 2005 Sep; 7(5):595-604. PubMed ID: 16050953
[TBL] [Abstract][Full Text] [Related]
10. Adenoviral vector-mediated glucagon-like peptide 1 gene therapy improves glucose homeostasis in Zucker diabetic fatty rats.
Lee Y; Kwon MK; Kang ES; Park YM; Choi SH; Ahn CW; Kim KS; Park CW; Cha BS; Kim SW; Sung JK; Lee EJ; Lee HC
J Gene Med; 2008 Mar; 10(3):260-8. PubMed ID: 18085721
[TBL] [Abstract][Full Text] [Related]
11. Bioactivity of a modified human Glucagon-like peptide-1.
Xu F; Wang KY; Wang N; Li G; Liu D
PLoS One; 2017; 12(2):e0171601. PubMed ID: 28152036
[TBL] [Abstract][Full Text] [Related]
12. Improved glycaemia in high-fat-fed neprilysin-deficient mice is associated with reduced DPP-4 activity and increased active GLP-1 levels.
Willard JR; Barrow BM; Zraika S
Diabetologia; 2017 Apr; 60(4):701-708. PubMed ID: 27933334
[TBL] [Abstract][Full Text] [Related]
13. Degradation, receptor binding, insulin secreting and antihyperglycaemic actions of palmitate-derivatised native and Ala8-substituted GLP-1 analogues.
Green BD; Gault VA; Mooney MH; Irwin N; Harriott P; Greer B; Bailey CJ; O'Harte FP; Flatt PR
Biol Chem; 2004 Feb; 385(2):169-77. PubMed ID: 15101559
[TBL] [Abstract][Full Text] [Related]
14. Anti-diabetic actions of glucagon-like peptide-1 on pancreatic beta-cells.
Lee YS; Jun HS
Metabolism; 2014 Jan; 63(1):9-19. PubMed ID: 24140094
[TBL] [Abstract][Full Text] [Related]
15. Engineered beta-cells secreting dipeptidyl peptidase IV-resistant glucagon-like peptide-1 show enhanced glucose-responsiveness.
Islam MS; Rahman SA; Mirzaei Z; Islam KB
Life Sci; 2005 Jan; 76(11):1239-48. PubMed ID: 15642594
[TBL] [Abstract][Full Text] [Related]
16. A GLP-1 receptor agonist conjugated to an albumin-binding domain for extended half-life.
Lindgren J; Refai E; Zaitsev SV; Abrahmsén L; Berggren PO; Karlström AE
Biopolymers; 2014 May; 102(3):252-9. PubMed ID: 24549714
[TBL] [Abstract][Full Text] [Related]
17. Dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1 which have extended metabolic stability and improved biological activity.
Deacon CF; Knudsen LB; Madsen K; Wiberg FC; Jacobsen O; Holst JJ
Diabetologia; 1998 Mar; 41(3):271-8. PubMed ID: 9541166
[TBL] [Abstract][Full Text] [Related]
18. Ezetimibe stimulates intestinal glucagon-like peptide 1 secretion via the MEK/ERK pathway rather than dipeptidyl peptidase 4 inhibition.
Chang E; Kim L; Choi JM; Park SE; Rhee EJ; Lee WY; Oh KW; Park SW; Park DI; Park CY
Metabolism; 2015 May; 64(5):633-41. PubMed ID: 25704082
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and metabolism studies on the glucagon-like peptide-1 (GLP-1)-derived metabolite GLP-1(9-36)amide in male Beagle dogs.
Eng H; Sharma R; McDonald TS; Landis MS; Stevens BD; Kalgutkar AS
Xenobiotica; 2014 Sep; 44(9):842-8. PubMed ID: 24588343
[TBL] [Abstract][Full Text] [Related]
20. Recombinant production of mGLP-1 by coupling of refolding and intein-mediated self-cleavage (CRIS).
Gao M; Tong Y; Tian H; Gao X; Yao W
Appl Microbiol Biotechnol; 2012 Dec; 96(5):1283-90. PubMed ID: 22644527
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
